
|Videos|June 19, 2017
Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC
Author(s)Alice T. Shaw, MD, PhD
Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Poll: Vote on the Top Abstracts to Watch at SABCS 2025
4
Early Silevertinib Data Lead to Phase 2 Trial Development
5








































